Prelude and its partner AbCellera to develop potent degraders/inhibitors as payloads for novel antibodies targeting tumor specific antigens
Next generation ADCs to extend the therapeutic utility of this class.
About
A seasoned team experienced in developing cancer medicines to create a fully integrated oncology company.